J. Christopher Naftzger - Jul 10, 2023 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role: General Counsel and CCO
Signature: /s/ David C. Hastings as attorney-in-fact for J. Christopher Naftzger
Stock symbol: ABUS
Transactions as of: Jul 10, 2023
Transactions value $: $0
Form type: 4
Date filed: 7/12/2023, 04:12 PM
Previous filing: Aug 15, 2022
Next filing: Feb 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABUS	Stock Option (Right to Buy)	Award	$0	+500K		$0.00	500K	Jul 10, 2023	Common Shares	500K	$2.26	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the closing price of the Issuer's common shares on the Nasdaq Stock Market on July 10, 2023, the date of the grant.
F2	This option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.

Content

Reflects the closing price of the Issuer's common shares on the Nasdaq Stock Market on July 10, 2023, the date of the grant.

This option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.